Key Insights
The Europe Companion Diagnostics Market is poised for significant expansion, with a current market size of USD 1.29 Billion and projected to grow at a Compound Annual Growth Rate (CAGR) of 9.23% during the forecast period of 2025-2033. This robust growth is primarily driven by the increasing prevalence of chronic diseases, particularly in the oncology sector, and the escalating demand for personalized medicine. Advancements in diagnostic technologies such as Immunohistochemistry (IHC), Polymerase Chain Reaction (PCR), and Gene Sequencing are crucial enablers, facilitating more accurate and targeted therapeutic interventions. The market's expansion is further fueled by supportive regulatory frameworks across European nations, encouraging the development and adoption of companion diagnostics. Key indications like Lung Cancer, Breast Cancer, and Colorectal Cancer are witnessing substantial investment in companion diagnostic development, reflecting their high disease burden and the need for precise patient stratification.
Europe Companion Diagnostics Market Market Size (In Billion)
The competitive landscape is characterized by the presence of major global players including Thermo Fisher Scientific Inc., Roche AG, and Abbott Laboratories, among others, actively engaged in research, development, and strategic collaborations. These companies are investing in innovative platforms and expanding their portfolios to cater to the evolving needs of healthcare providers and patients. Emerging trends indicate a strong focus on liquid biopsy technologies and the integration of artificial intelligence (AI) in diagnostic workflows to enhance efficiency and diagnostic accuracy. However, certain restraints such as the high cost of development and implementation, along with varying reimbursement policies across European countries, could pose challenges to market penetration. Despite these hurdles, the undeniable clinical utility of companion diagnostics in improving patient outcomes and optimizing treatment efficacy is expected to drive sustained growth in the European market.
Europe Companion Diagnostics Market Company Market Share
Europe Companion Diagnostics Market: Unlocking Precision Medicine with Advanced Biomarker Testing
This comprehensive report offers an in-depth analysis of the Europe companion diagnostics (CDx) market, providing critical insights for stakeholders navigating this dynamic sector. The market is driven by the increasing demand for personalized medicine, advancements in genomic technologies, and a growing understanding of the importance of targeted therapies in treating complex diseases. Covering the Study Period: 2019–2033, with a Base Year of 2025, the report delves into the Market Size and CAGR to forecast robust growth. This analysis will guide strategic decisions for pharmaceutical companies, diagnostic manufacturers, research institutions, and investors seeking to capitalize on the burgeoning Europe Companion Diagnostics Market.
Europe Companion Diagnostics Market Market Concentration & Dynamics
The Europe companion diagnostics market exhibits a moderate to high concentration, characterized by strategic collaborations and a few dominant players. Innovation ecosystems are thriving, fueled by extensive R&D investments and the growing prevalence of oncology and rare diseases, which are primary beneficiaries of companion diagnostic applications. Regulatory frameworks, particularly stringent in the EU, are continuously evolving to accommodate novel CDx technologies, emphasizing both analytical and clinical validation. Substitute products are limited due to the highly specific nature of CDx for targeted therapies, making genuine substitutes scarce. End-user trends indicate a strong preference for diagnostic solutions that offer early disease detection, prognostic information, and predictive markers for treatment selection. Mergers and acquisition (M&A) activities are significant, reflecting the consolidation trend and the pursuit of synergistic capabilities. The market has witnessed numerous M&A deal counts, particularly involving companies seeking to expand their technological portfolios or market reach. Key M&A activities aim to integrate diagnostic capabilities with drug development pipelines, enhancing the value proposition for both diagnostics and therapeutics.
Europe Companion Diagnostics Market Industry Insights & Trends
The Europe companion diagnostics market is experiencing significant growth, propelled by several key factors. The escalating burden of chronic diseases, particularly cancer, is a primary driver, necessitating more precise and effective treatment strategies. Companion diagnostics play a crucial role in identifying patient populations most likely to respond to specific therapies, thereby improving treatment outcomes and reducing healthcare costs associated with ineffective treatments. Technological advancements, especially in Gene Sequencing, Polymerase Chain Reaction (PCR), and Immunohistochemistry (IHC), are continually expanding the scope of detectable biomarkers. This enables the development of novel CDx assays for a wider range of indications. The increasing focus on personalized medicine by regulatory bodies and healthcare payers further fuels market expansion, as CDx solutions align with the principles of tailored treatment approaches. Evolving consumer behaviors, including greater patient engagement in healthcare decisions and a demand for more targeted and less toxic therapies, also contribute to the growing adoption of companion diagnostics. The overall Market Size is projected to witness a substantial CAGR over the forecast period, driven by these underlying trends. The shift towards proactive healthcare and the integration of diagnostics into early disease management protocols are creating new avenues for growth.
Key Markets & Segments Leading Europe Companion Diagnostics Market
The Europe companion diagnostics market is led by Lung Cancer and Breast Cancer indications, which represent significant market share due to their high prevalence and the established availability of targeted therapies with corresponding CDx tests. Gene Sequencing and Immunohistochemistry (IHC) are the dominant technologies, offering high sensitivity and specificity for identifying genetic mutations and protein expression levels crucial for therapeutic decisions.
Dominant Regions & Countries: Germany, the United Kingdom, and France are leading markets within Europe, driven by advanced healthcare infrastructure, strong pharmaceutical R&D presence, and favorable regulatory environments for diagnostic innovations. Economic growth and increased healthcare spending in these nations further bolster the adoption of CDx.
Leading Segments:
- Technology:
- Gene Sequencing: Drives innovation with its ability to identify complex genetic alterations, essential for advanced oncology treatments.
- Immunohistochemistry (IHC): Remains a cornerstone for protein-based biomarker detection, crucial for many established targeted therapies.
- Polymerase Chain Reaction (PCR): Offers high sensitivity and speed for detecting specific genetic sequences.
- In-situ Hybridization (ISH): Provides spatial information about biomarker expression within tissue.
- Indication:
- Lung Cancer: A major driver due to the proliferation of targeted therapies like EGFR inhibitors and ALK inhibitors, each requiring specific CDx tests.
- Breast Cancer: Significant market share driven by HER2 testing and hormone receptor status, with emerging biomarkers for new therapeutic classes.
- Colorectal Cancer: Driven by KRAS, NRAS, and BRAF mutation testing for anti-EGFR therapies.
- Leukemia & Melanoma: Growing segments with increasing development of targeted agents and corresponding CDx.
- Technology:
The robust pipeline of targeted therapies and the increasing reimbursement for companion diagnostic tests are critical drivers for sustained dominance in these segments.
Europe Companion Diagnostics Market Product Developments
Product development in the Europe companion diagnostics market is intensely focused on enhancing multiplexing capabilities, improving assay speed and accuracy, and expanding the range of detectable biomarkers. Innovations are geared towards integrating multiple tests into single platforms, streamlining workflow for laboratories, and providing actionable insights for clinicians. For instance, the CE-IVD marking of Illumina, Inc.'s TruSight Oncology (TSO) Comprehensive (EU) test signifies a significant advancement in comprehensive genomic profiling for CDx applications. Similarly, the development of PD-L1 IHC assays by companies like Agilent Technologies Inc. for specific cancer types demonstrates the trend of assay development tailored to particular drug-biomarker pairs. These advancements are crucial for competitive advantage, enabling earlier and more precise patient stratification for novel and existing therapies.
Challenges in the Europe Companion Diagnostics Market Market
The Europe companion diagnostics market faces several challenges that can hinder its growth trajectory. Stringent and evolving regulatory pathways, requiring extensive validation for both analytical and clinical utility, can lead to prolonged approval timelines and increased development costs. Reimbursement policies across different European countries can be fragmented and inconsistent, impacting market access and adoption rates. Furthermore, the complexity of supply chain management for specialized reagents and instrumentation, coupled with the need for skilled personnel to perform and interpret complex assays, presents operational hurdles. Intense competition among diagnostic companies and the increasing pressure to demonstrate cost-effectiveness to healthcare payers also pose significant challenges. The market size is significantly influenced by these factors.
Forces Driving Europe Companion Diagnostics Market Growth
The Europe companion diagnostics market is propelled by powerful forces that ensure its continued expansion. The relentless rise in cancer incidence and prevalence across Europe necessitates more effective and personalized treatment strategies. This creates a strong demand for CDx to identify patients who will benefit most from targeted therapies. Advances in molecular biology and genomics have unlocked the discovery of novel biomarkers, paving the way for new companion diagnostic test development. Furthermore, increased investment in pharmaceutical R&D, with a growing emphasis on precision medicine, directly fuels the need for companion diagnostics to support drug development and approval. Favorable reimbursement policies in several key European markets are also encouraging the adoption of CDx solutions by making them more accessible to patients.
Challenges in the Europe Companion Diagnostics Market Market
Long-term growth catalysts for the Europe companion diagnostics market are deeply rooted in innovation and strategic expansion. The ongoing advancements in next-generation sequencing (NGS) technologies are continuously expanding the scope of detectable biomarkers, opening up new therapeutic avenues. Strategic partnerships between pharmaceutical and diagnostic companies are crucial for co-developing companion diagnostics hand-in-hand with novel drugs, ensuring seamless integration from discovery to clinical practice. Market expansion into less developed European regions, alongside a greater focus on rare diseases and non-oncology indications, represents significant untapped potential. The increasing emphasis on proactive disease management and early intervention, supported by diagnostic screening, will further solidify the role of companion diagnostics in the healthcare landscape.
Emerging Opportunities in Europe Companion Diagnostics Market
Emerging opportunities in the Europe companion diagnostics market are ripe for exploitation by agile stakeholders. The growing field of liquid biopsies presents a transformative opportunity, offering minimally invasive methods for biomarker detection and monitoring, thereby expanding the utility of CDx beyond traditional tissue samples. Increased focus on immunotherapy and the development of predictive biomarkers for patient response to these therapies is a rapidly growing area. Furthermore, the expansion of CDx applications into new therapeutic areas beyond oncology, such as neurology and autoimmune diseases, presents substantial growth potential. The digitalization of healthcare and the integration of AI in diagnostic interpretation and data analysis are poised to enhance efficiency and diagnostic accuracy, creating further opportunities.
Leading Players in the Europe Companion Diagnostics Market Sector
- Thermo Fisher Scientific Inc.
- BioMerieux SA
- Siemens Healthineers
- Abbott Laboratories
- Qiagen Inc
- F Hoffmann-La Roche AG
- Beckman Coulter Inc (Danaher Corporation)
- Agilent Technologies
Key Milestones in Europe Companion Diagnostics Market Industry
- August 2022: BD (Becton, Dickinson, and Company) announced a collaboration agreement with Labcorp for creating a framework to develop, manufacture, market, and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases.
- May 2022: Agilent Technologies Inc. announced that its PD-L1 IHC 22C3 pharmDx, Code SK006, is now EU CE-IVD-marked for use in cervical cancer. PD-L1 IHC 22C3 pharmDx can be used as an aid in identifying cervical cancer patients for whom treatment with KEYTRUDA (pembrolizumab) may be appropriate.
- May 2022: Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight Oncology (TSO) Comprehensive (EU) test.
- April 2022: Amoy Diagnostics Co. announced that they have entered into a master collaboration agreement with AstraZeneca in China, Europe, and Japan, for developing and commercializing AmoyDx assays that may cover any type of indication or biomarker for companion diagnostic (CDx) use with AstraZeneca medicines.
These milestones highlight strategic partnerships, regulatory approvals, and technological advancements that are shaping the market landscape.
Strategic Outlook for Europe Companion Diagnostics Market Market
The strategic outlook for the Europe companion diagnostics market is exceptionally positive, driven by an intensifying focus on precision medicine and personalized healthcare. Growth accelerators will include the continued expansion of targeted therapy pipelines, necessitating robust CDx development. Investment in emerging technologies like liquid biopsies and advanced genomic platforms will further enhance diagnostic capabilities. Strategic collaborations between pharmaceutical giants and diagnostic innovators will remain paramount, fostering the co-development of integrated treatment solutions. Furthermore, proactive engagement with regulatory bodies and payers to streamline approval and reimbursement processes will be critical for market penetration. The market's future potential lies in its ability to demonstrably improve patient outcomes and optimize healthcare resource utilization.
Europe Companion Diagnostics Market Segmentation
-
1. Technology
- 1.1. Immunohistochemistry (IHC)
- 1.2. Polymerase Chain Reaction (PCR)
- 1.3. In-situ Hybridization (ISH)
- 1.4. Gene Sequencing
- 1.5. Other Technologies
-
2. Indication
- 2.1. Lung Cancer
- 2.2. Breast Cancer
- 2.3. Colorectal Cancer
- 2.4. Leukemia
- 2.5. Melanoma
- 2.6. Other Indications
Europe Companion Diagnostics Market Segmentation By Geography
- 1. Germany
- 2. United Kingdom
- 3. France
- 4. Italy
- 5. Spain
- 6. Rest of Europe
Europe Companion Diagnostics Market Regional Market Share
Geographic Coverage of Europe Companion Diagnostics Market
Europe Companion Diagnostics Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 9.23% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rising Demand for Personalized Medicine and Targeted Therapy; Rise in Biomarker Discovery; Rising Prevalence of Chronic Diseases
- 3.3. Market Restrains
- 3.3.1. High Cost of Drug Development and Associated Clinical Trials; High Reimbursement Issues Associated with Personalized Medicines
- 3.4. Market Trends
- 3.4.1. Immunohistochemistry Segment is Estimated to Register Significant Growth over the Forecast Period.
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Technology
- 5.1.1. Immunohistochemistry (IHC)
- 5.1.2. Polymerase Chain Reaction (PCR)
- 5.1.3. In-situ Hybridization (ISH)
- 5.1.4. Gene Sequencing
- 5.1.5. Other Technologies
- 5.2. Market Analysis, Insights and Forecast - by Indication
- 5.2.1. Lung Cancer
- 5.2.2. Breast Cancer
- 5.2.3. Colorectal Cancer
- 5.2.4. Leukemia
- 5.2.5. Melanoma
- 5.2.6. Other Indications
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. Germany
- 5.3.2. United Kingdom
- 5.3.3. France
- 5.3.4. Italy
- 5.3.5. Spain
- 5.3.6. Rest of Europe
- 5.1. Market Analysis, Insights and Forecast - by Technology
- 6. Germany Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Technology
- 6.1.1. Immunohistochemistry (IHC)
- 6.1.2. Polymerase Chain Reaction (PCR)
- 6.1.3. In-situ Hybridization (ISH)
- 6.1.4. Gene Sequencing
- 6.1.5. Other Technologies
- 6.2. Market Analysis, Insights and Forecast - by Indication
- 6.2.1. Lung Cancer
- 6.2.2. Breast Cancer
- 6.2.3. Colorectal Cancer
- 6.2.4. Leukemia
- 6.2.5. Melanoma
- 6.2.6. Other Indications
- 6.1. Market Analysis, Insights and Forecast - by Technology
- 7. United Kingdom Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Technology
- 7.1.1. Immunohistochemistry (IHC)
- 7.1.2. Polymerase Chain Reaction (PCR)
- 7.1.3. In-situ Hybridization (ISH)
- 7.1.4. Gene Sequencing
- 7.1.5. Other Technologies
- 7.2. Market Analysis, Insights and Forecast - by Indication
- 7.2.1. Lung Cancer
- 7.2.2. Breast Cancer
- 7.2.3. Colorectal Cancer
- 7.2.4. Leukemia
- 7.2.5. Melanoma
- 7.2.6. Other Indications
- 7.1. Market Analysis, Insights and Forecast - by Technology
- 8. France Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Technology
- 8.1.1. Immunohistochemistry (IHC)
- 8.1.2. Polymerase Chain Reaction (PCR)
- 8.1.3. In-situ Hybridization (ISH)
- 8.1.4. Gene Sequencing
- 8.1.5. Other Technologies
- 8.2. Market Analysis, Insights and Forecast - by Indication
- 8.2.1. Lung Cancer
- 8.2.2. Breast Cancer
- 8.2.3. Colorectal Cancer
- 8.2.4. Leukemia
- 8.2.5. Melanoma
- 8.2.6. Other Indications
- 8.1. Market Analysis, Insights and Forecast - by Technology
- 9. Italy Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Technology
- 9.1.1. Immunohistochemistry (IHC)
- 9.1.2. Polymerase Chain Reaction (PCR)
- 9.1.3. In-situ Hybridization (ISH)
- 9.1.4. Gene Sequencing
- 9.1.5. Other Technologies
- 9.2. Market Analysis, Insights and Forecast - by Indication
- 9.2.1. Lung Cancer
- 9.2.2. Breast Cancer
- 9.2.3. Colorectal Cancer
- 9.2.4. Leukemia
- 9.2.5. Melanoma
- 9.2.6. Other Indications
- 9.1. Market Analysis, Insights and Forecast - by Technology
- 10. Spain Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Technology
- 10.1.1. Immunohistochemistry (IHC)
- 10.1.2. Polymerase Chain Reaction (PCR)
- 10.1.3. In-situ Hybridization (ISH)
- 10.1.4. Gene Sequencing
- 10.1.5. Other Technologies
- 10.2. Market Analysis, Insights and Forecast - by Indication
- 10.2.1. Lung Cancer
- 10.2.2. Breast Cancer
- 10.2.3. Colorectal Cancer
- 10.2.4. Leukemia
- 10.2.5. Melanoma
- 10.2.6. Other Indications
- 10.1. Market Analysis, Insights and Forecast - by Technology
- 11. Rest of Europe Europe Companion Diagnostics Market Analysis, Insights and Forecast, 2020-2032
- 11.1. Market Analysis, Insights and Forecast - by Technology
- 11.1.1. Immunohistochemistry (IHC)
- 11.1.2. Polymerase Chain Reaction (PCR)
- 11.1.3. In-situ Hybridization (ISH)
- 11.1.4. Gene Sequencing
- 11.1.5. Other Technologies
- 11.2. Market Analysis, Insights and Forecast - by Indication
- 11.2.1. Lung Cancer
- 11.2.2. Breast Cancer
- 11.2.3. Colorectal Cancer
- 11.2.4. Leukemia
- 11.2.5. Melanoma
- 11.2.6. Other Indications
- 11.1. Market Analysis, Insights and Forecast - by Technology
- 12. Competitive Analysis
- 12.1. Market Share Analysis 2025
- 12.2. Company Profiles
- 12.2.1 Thermo Fisher Scientific Inc *List Not Exhaustive
- 12.2.1.1. Overview
- 12.2.1.2. Products
- 12.2.1.3. SWOT Analysis
- 12.2.1.4. Recent Developments
- 12.2.1.5. Financials (Based on Availability)
- 12.2.2 BioMerieux SA
- 12.2.2.1. Overview
- 12.2.2.2. Products
- 12.2.2.3. SWOT Analysis
- 12.2.2.4. Recent Developments
- 12.2.2.5. Financials (Based on Availability)
- 12.2.3 Siemens Healthineers
- 12.2.3.1. Overview
- 12.2.3.2. Products
- 12.2.3.3. SWOT Analysis
- 12.2.3.4. Recent Developments
- 12.2.3.5. Financials (Based on Availability)
- 12.2.4 Abbott Laboratories
- 12.2.4.1. Overview
- 12.2.4.2. Products
- 12.2.4.3. SWOT Analysis
- 12.2.4.4. Recent Developments
- 12.2.4.5. Financials (Based on Availability)
- 12.2.5 Qiagen Inc
- 12.2.5.1. Overview
- 12.2.5.2. Products
- 12.2.5.3. SWOT Analysis
- 12.2.5.4. Recent Developments
- 12.2.5.5. Financials (Based on Availability)
- 12.2.6 F Hoffmann-La Roche AG
- 12.2.6.1. Overview
- 12.2.6.2. Products
- 12.2.6.3. SWOT Analysis
- 12.2.6.4. Recent Developments
- 12.2.6.5. Financials (Based on Availability)
- 12.2.7 Beckman Coulter Inc (Danaher Corporation)
- 12.2.7.1. Overview
- 12.2.7.2. Products
- 12.2.7.3. SWOT Analysis
- 12.2.7.4. Recent Developments
- 12.2.7.5. Financials (Based on Availability)
- 12.2.8 Agilent Technologies
- 12.2.8.1. Overview
- 12.2.8.2. Products
- 12.2.8.3. SWOT Analysis
- 12.2.8.4. Recent Developments
- 12.2.8.5. Financials (Based on Availability)
- 12.2.1 Thermo Fisher Scientific Inc *List Not Exhaustive
List of Figures
- Figure 1: Europe Companion Diagnostics Market Revenue Breakdown (Million, %) by Product 2025 & 2033
- Figure 2: Europe Companion Diagnostics Market Share (%) by Company 2025
List of Tables
- Table 1: Europe Companion Diagnostics Market Revenue Million Forecast, by Technology 2020 & 2033
- Table 2: Europe Companion Diagnostics Market Volume K Units Forecast, by Technology 2020 & 2033
- Table 3: Europe Companion Diagnostics Market Revenue Million Forecast, by Indication 2020 & 2033
- Table 4: Europe Companion Diagnostics Market Volume K Units Forecast, by Indication 2020 & 2033
- Table 5: Europe Companion Diagnostics Market Revenue Million Forecast, by Region 2020 & 2033
- Table 6: Europe Companion Diagnostics Market Volume K Units Forecast, by Region 2020 & 2033
- Table 7: Europe Companion Diagnostics Market Revenue Million Forecast, by Technology 2020 & 2033
- Table 8: Europe Companion Diagnostics Market Volume K Units Forecast, by Technology 2020 & 2033
- Table 9: Europe Companion Diagnostics Market Revenue Million Forecast, by Indication 2020 & 2033
- Table 10: Europe Companion Diagnostics Market Volume K Units Forecast, by Indication 2020 & 2033
- Table 11: Europe Companion Diagnostics Market Revenue Million Forecast, by Country 2020 & 2033
- Table 12: Europe Companion Diagnostics Market Volume K Units Forecast, by Country 2020 & 2033
- Table 13: Europe Companion Diagnostics Market Revenue Million Forecast, by Technology 2020 & 2033
- Table 14: Europe Companion Diagnostics Market Volume K Units Forecast, by Technology 2020 & 2033
- Table 15: Europe Companion Diagnostics Market Revenue Million Forecast, by Indication 2020 & 2033
- Table 16: Europe Companion Diagnostics Market Volume K Units Forecast, by Indication 2020 & 2033
- Table 17: Europe Companion Diagnostics Market Revenue Million Forecast, by Country 2020 & 2033
- Table 18: Europe Companion Diagnostics Market Volume K Units Forecast, by Country 2020 & 2033
- Table 19: Europe Companion Diagnostics Market Revenue Million Forecast, by Technology 2020 & 2033
- Table 20: Europe Companion Diagnostics Market Volume K Units Forecast, by Technology 2020 & 2033
- Table 21: Europe Companion Diagnostics Market Revenue Million Forecast, by Indication 2020 & 2033
- Table 22: Europe Companion Diagnostics Market Volume K Units Forecast, by Indication 2020 & 2033
- Table 23: Europe Companion Diagnostics Market Revenue Million Forecast, by Country 2020 & 2033
- Table 24: Europe Companion Diagnostics Market Volume K Units Forecast, by Country 2020 & 2033
- Table 25: Europe Companion Diagnostics Market Revenue Million Forecast, by Technology 2020 & 2033
- Table 26: Europe Companion Diagnostics Market Volume K Units Forecast, by Technology 2020 & 2033
- Table 27: Europe Companion Diagnostics Market Revenue Million Forecast, by Indication 2020 & 2033
- Table 28: Europe Companion Diagnostics Market Volume K Units Forecast, by Indication 2020 & 2033
- Table 29: Europe Companion Diagnostics Market Revenue Million Forecast, by Country 2020 & 2033
- Table 30: Europe Companion Diagnostics Market Volume K Units Forecast, by Country 2020 & 2033
- Table 31: Europe Companion Diagnostics Market Revenue Million Forecast, by Technology 2020 & 2033
- Table 32: Europe Companion Diagnostics Market Volume K Units Forecast, by Technology 2020 & 2033
- Table 33: Europe Companion Diagnostics Market Revenue Million Forecast, by Indication 2020 & 2033
- Table 34: Europe Companion Diagnostics Market Volume K Units Forecast, by Indication 2020 & 2033
- Table 35: Europe Companion Diagnostics Market Revenue Million Forecast, by Country 2020 & 2033
- Table 36: Europe Companion Diagnostics Market Volume K Units Forecast, by Country 2020 & 2033
- Table 37: Europe Companion Diagnostics Market Revenue Million Forecast, by Technology 2020 & 2033
- Table 38: Europe Companion Diagnostics Market Volume K Units Forecast, by Technology 2020 & 2033
- Table 39: Europe Companion Diagnostics Market Revenue Million Forecast, by Indication 2020 & 2033
- Table 40: Europe Companion Diagnostics Market Volume K Units Forecast, by Indication 2020 & 2033
- Table 41: Europe Companion Diagnostics Market Revenue Million Forecast, by Country 2020 & 2033
- Table 42: Europe Companion Diagnostics Market Volume K Units Forecast, by Country 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Europe Companion Diagnostics Market?
The projected CAGR is approximately 9.23%.
2. Which companies are prominent players in the Europe Companion Diagnostics Market?
Key companies in the market include Thermo Fisher Scientific Inc *List Not Exhaustive, BioMerieux SA, Siemens Healthineers, Abbott Laboratories, Qiagen Inc, F Hoffmann-La Roche AG, Beckman Coulter Inc (Danaher Corporation), Agilent Technologies.
3. What are the main segments of the Europe Companion Diagnostics Market?
The market segments include Technology, Indication.
4. Can you provide details about the market size?
The market size is estimated to be USD 1.29 Million as of 2022.
5. What are some drivers contributing to market growth?
Rising Demand for Personalized Medicine and Targeted Therapy; Rise in Biomarker Discovery; Rising Prevalence of Chronic Diseases.
6. What are the notable trends driving market growth?
Immunohistochemistry Segment is Estimated to Register Significant Growth over the Forecast Period..
7. Are there any restraints impacting market growth?
High Cost of Drug Development and Associated Clinical Trials; High Reimbursement Issues Associated with Personalized Medicines.
8. Can you provide examples of recent developments in the market?
August 2022: BD (Becton, Dickinson, and Company) announced a collaboration agreement with Labcorp for creating a framework to develop, manufacture, market, and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million and volume, measured in K Units.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Europe Companion Diagnostics Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Europe Companion Diagnostics Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Europe Companion Diagnostics Market?
To stay informed about further developments, trends, and reports in the Europe Companion Diagnostics Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence